Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: A historical, prospective secondary analysis

Journal of Neurology, Neurosurgery and Psychiatry

Volumn 87, Issue 1, 2016, Pages 106-112

  Arrighi, H Michael ^a   Barakos, Jerome ^b,c   Barkhof, Frederik ^d   Tampieri, Donatella ^e   Jack, Clifford ^f   Melançon, Denis ^f   Morris, Kristen ^g,h   Ketter, Nzeera ^a   Liu, Enchi ^a   Brashear, H Robert ^a  

^a JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

^b CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^c SYNARC INC   (United States)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e NEURORX RESEARCH   (Canada)

^f MAYO CLINIC   (United States)

^g Janssen Alzheimer Immunotherapy RandD ^*  (United States)

^h BIOMARIN PHARMACEUTICAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTICOAGULANT AGENT; APOLIPOPROTEIN E4; BAPINEUZUMAB; HEMOSIDERIN; PLACEBO; FIBRINOLYTIC AGENT; MONOCLONAL ANTIBODY; NOOTROPIC AGENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN HEMORRHAGE; CEREBROVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DRUG DOSE INCREASE; FEMALE; GENOTYPE; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; MINI MENTAL STATE EXAMINATION; MULTICENTER STUDY (TOPIC); NEURORADIOLOGIST; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK FACTOR; SECONDARY ANALYSIS; AMYLOID PLAQUE; ANTAGONISTS AND INHIBITORS; BLOOD; COMPLICATION; DOSE RESPONSE; MIDDLE AGED; NEUROIMAGING; PATHOLOGY; STROKE; VERY ELDERLY; WHITE MATTER;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANTIBODIES, MONOCLONAL, HUMANIZED; APOLIPOPROTEIN E4; CLINICAL TRIALS, PHASE II AS TOPIC; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FIBRINOLYTIC AGENTS; HEMOSIDERIN; HUMANS; MALE; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; NEUROIMAGING; NOOTROPIC AGENTS; PLAQUE, AMYLOID; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; STROKE; WHITE MATTER;

EID: 84956581698     PISSN: 00223050     EISSN: 1468330X     Source Type: Journal    
DOI: 10.1136/jnnp-2014-309493     Document Type: Article

References (25)

1. Jeerakathil T, Wolf PA, Beiser A, et al. Cerebral microbleeds: prevalence and associations with cardiovascular risk factors in the Framingham study. Stroke 2004;35:1831-5.
2. Vernooji MW, van der Lugt A, Ikram MA, et al. Prevalence and risk factors of cerebral microbleeds: the Rotterdam Scan Study. Neurol 2008;70:1208-14.
3. Cordonnier C, van der Flier WM, Sluimer JD, et al. Prevalence and severity of microbleeds in a memory clinic setting. Neurol 2006;66:1356-60.
4. Hanyu H, Tanaka Y, Shimizu S, et al. Cerebral microbleeds in Alzheimer's disease. J Neurol 2003;250:1496-7.
5. Nakata-Kudo Y, Mizuno T, Yamada K, et al. Microbleeds in Alzheimer disease are more related to cerebral amyloid angiopathy than cerebrovascular disease. Dement Geriatr Cogn Disord 2006;22:8-14.
6. Pettersen JA, Sathiyamoorthy G, Gao FQ, et al. Microbleed topography, leukoaraiosis, and cognition in probably Alzheimer disease from the Sunnybrook dementia study. Arch Neurol 2008;65:790-5.
7. Cordonnier C, Al-Shahi Salman R, Wardlaw J. Spontaneous brain microbleeds: systematic review, subgroup analyses and standards for study design. Brain 2007;130:1988-2003.
8. Goos JDC, Teunissen CE, Veerhuis R, et al. Microbleeds related to altered amyloidbeta metabolism in Alzheimer's disease. Neurobiol Aging 2012;33:1011.e1-9.
9. Sperling RA, Jack CR Jr, Black SE, et al. Amyloid-related imaging abnormalities in amyloid-modifying therapeutic trials: recommendations from the Alzheimer's Association Research Roundtable Workgroup. Alzheimer Dement 2011;7:367-85.
10. Zago W, Schroeter S, Guido T, et al. Vascular alterations in PDAPP mice after anti-A immunotherapy: implications for amyloid-related imaging abnormalities. Alzheimer Dement 2013;9:S105-15.
11. Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol 2010;9:363-72.
12. Salloway S, Sperling R, Gilman S, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. Neurology 2009;73:2061-70.
13. Gregoire SM, Chaudhary UJ, Brown MM, et al. The Microbleed Anatomical Rating Scale (MARS): reliability of a tool to map brain microbleeds. Neurology 2009;73:1759-66.
14. Wahlund LO, Barkhof F, Fazekas F, et al. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001;32:1318-22.
15. Tolappanen AM, Lavikainen P, Soloman A, et al. Incidence of stroke in people with Alzheimer disease: a national register-based approach. Neurology 2013;80:353-8.
16. Salloway S, Sperling R, Fox NC, et al. Bapineuzumab 301 and 302 Clinical Trial Investigators. Two phase 3 trials of Bapineuzumab in mild-to-moderate Alzheimer's disease. New Eng J Med 2014;370:322-33.
17. Greenberg SM, Rebeck GW, Vonsattel JPG, et al. Apolipoprotein E epsilon 4 and cerebral hemorrahge associated with amyloid angioapathy. Ann Neurol 1995;38:254-9.
18. Goos JDC, Henneman WJP, Sluimer JD, et al. Incidence of cerebral microbleeds: a longitudinal study in a memory clinic population. Neurol 2010;74:1954-60.
19. Goos JDC, Kester MI, Barkhof F, et al. Patients with Alzheimer disease with multiple microbleeds: relationship with cerebrospinal fluid biomarkers and cognition. Stroke 2009;49:3455-60.
20. Loehrer E, Ikram MA, Akoudad S, et al. Apolipoprotein E genotype influences spatial distribution of microbleeds. Neurobiol Aging 2014;35:899-905.
21. Caselli RJ, Walker D, Sue L, et al. Amyloid load in nondemented brains correlates with APOE e4. Neurosci Lett 2010;473:168-71.
22. Pfeifer M, Boncristiano S, Bondolfi L, et al. Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science 2002;298:1379.
23. Boche D, Zotova E, Weller RO, et al. Consequences of Aβ immunisation on the vasculature of human Alzheimer's disease brain. Brain 2008;131:3299-310.
24. Greenberg SM, O'Donnell HC, Schaefer PW, et al. MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy. Neurology 1999;53:1135-8.
25. Kirsch W, McAuley G, Holshouser B, et al. Serial susceptibility weighted MRI measures brain iron and microbleeds in dementia. J Alzheimers Dis 2009;17:599-609.